upp-1 Antibody

What is UPP1 and what is its biological significance in research?

UPP1 (Uridine Phosphorylase 1) is an enzyme that catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate. It belongs to the PNP/UDP phosphorylase protein family and plays a critical role in the salvage pathway for nucleotide synthesis, making it essential for cellular proliferation and growth . The canonical human UPP1 protein has 310 amino acid residues with a molecular mass of approximately 33.9 kDa, and up to two different isoforms have been reported . UPP1 is particularly significant in research because its dysregulation has been linked to various diseases, including cancer and metabolic disorders, making it an important target for antibody-based detection in experimental studies .

What are the optimal experimental applications for UPP1 antibodies?

UPP1 antibodies have been validated for multiple experimental applications with specific methodological considerations for each:

Researchers should select the appropriate application based on their specific experimental questions, with Western blot being the most commonly used technique for detecting UPP1 protein expression levels .

What tissues and cell types should be used as positive controls for UPP1 antibody validation?

When validating UPP1 antibodies, selecting appropriate positive controls is essential. Based on tissue expression patterns, the following samples have been confirmed to express UPP1 and can serve as reliable positive controls:

• Human tissues: Small intestine, oral mucosa, esophagus, duodenum, and appendix show notable UPP1 expression

• Cell lines: HeLa and 293T cells are recommended positive controls for Western blot applications

• Animal tissues: Rat large intestine, lung, and heart; mouse large intestine, lung, and kidney have been validated as positive samples

For immunohistochemistry applications specifically, mouse small intestine tissue has been confirmed as an effective positive control, though researchers should note that antigen retrieval with TE buffer pH 9.0 is recommended for optimal results .

What is the relationship between UPP1 and cancer research?

Mechanistically, UPP1 upregulation leads to increased release of various immunosuppressive cytokines (particularly TGF-β1) and elevates PD-L1 expression through the PI3K/AKT/mTOR pathway, contributing to CD8+ T cell suppression . Furthermore, UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil increases fibronectin deposition in the extracellular microenvironment . These findings highlight the value of UPP1 antibodies in studying cancer immunosuppression and metastasis mechanisms.

How should researchers optimize antibody dilutions for different UPP1 detection methods?

Optimal antibody dilution varies by detection method and specific antibody product. Based on validated protocols, the following guidelines can help researchers optimize their experiments:

For Western blot applications, start with a dilution range of 1:500-1:2000 . When using immunohistochemistry, begin with 1:50-1:500 dilution range . For both methods, researchers should perform a dilution series experiment to determine the optimal concentration that provides the best signal-to-noise ratio for their specific sample types.

For novel applications or sample types, a preliminary titration experiment is essential. Prepare a series of dilutions (e.g., 1:100, 1:500, 1:1000, 1:5000) and test them in parallel on the same blot or tissue section. Evaluate results based on:

• Signal intensity at the expected molecular weight (33.9 kDa for UPP1)

• Background noise levels

• Signal specificity (absence of non-specific bands)

Remember that dilution requirements may vary depending on antibody affinity, sample preparation method, and protein expression levels in your experimental system.

What are the critical methodological considerations for UPP1 immunohistochemistry?

Successful UPP1 immunohistochemistry requires attention to several critical methodological factors:

Fixation and Tissue Processing:

• Formalin-fixed, paraffin-embedded (FFPE) tissues are commonly used

• Optimal fixation time (typically 24 hours) is crucial to preserve antigenicity

Antigen Retrieval:

• TE buffer at pH 9.0 is strongly recommended for UPP1 detection

• Alternative approach: citrate buffer at pH 6.0 may be used with potentially different results

• Heat-induced epitope retrieval (pressure cooker or microwave) typically yields better results than enzymatic retrieval

Blocking and Antibody Incubation:

• Use appropriate blocking serum (typically 5-10% normal serum from the same species as secondary antibody)

• Primary antibody should be incubated at optimal dilution (1:50-1:500)

• Overnight incubation at 4°C often provides better staining than shorter incubations

Controls:

• Always include positive control tissue (mouse small intestine recommended)

• Include negative controls (primary antibody omission, isotype control)

• Consider using specimens with known differential expression of UPP1 (like tumor vs. normal tissue)

Researchers should document their exact protocol, including incubation times, temperatures, and buffer compositions to ensure reproducibility.

How can researchers verify the specificity of UPP1 antibodies?

Verifying antibody specificity is crucial for reliable research results. For UPP1 antibodies, consider implementing these validation approaches:

Genetic Validation:

• Use cells with UPP1 knockout/knockdown (via CRISPR-Cas9 or siRNA)

• Compare staining patterns between wild-type and UPP1-depleted samples

• Loss of signal in UPP1-depleted samples confirms specificity

Protein Validation:

• Perform peptide competition assays using the immunizing peptide

• Pre-incubate antibody with excess target peptide before application

• Significant signal reduction indicates specificity

Orthogonal Validation:

• Compare results using different UPP1 antibodies targeting distinct epitopes

• Correlate protein detection with mRNA expression data

• Confirm subcellular localization matches known distribution (cytosol, nucleoplasm)

Migration Validation for Western Blot:

• Verify that detected protein band matches expected molecular weight (33.9 kDa)

• Check for appropriate tissue/cell type expression pattern

These validation steps should be documented in publications to strengthen the reliability of research findings involving UPP1 antibodies.

How can UPP1 antibodies be used to investigate tumor microenvironment interactions?

UPP1 antibodies are valuable tools for investigating tumor microenvironment (TME) interactions, particularly in relation to immunosuppression and metastasis. Recent research has revealed that UPP1high tumor cells significantly influence the TME . Researchers can utilize UPP1 antibodies in the following advanced applications:

Multiplex Immunofluorescence Staining:

• Co-stain UPP1 with immune cell markers (CD8, CD4, neutrophil markers)

• Analyze spatial relationships between UPP1high tumor cells and immune infiltrates

• Identify UPP1high tumor cells at invasive tumor fronts, where they predominantly localize

Cytokine Profiling:

• Use UPP1 antibodies to sort UPP1high vs. UPP1low tumor cells

• Analyze differential cytokine secretion profiles (particularly TGF-β1, GM-CSF, IL-1β, IL-6)

• Correlate UPP1 expression with immunosuppressive cytokine levels in patient samples

Single-Cell Analysis:

• Combine UPP1 antibody staining with single-cell RNA sequencing

• Identify UPP1-associated gene signatures

• Correlate UPP1 expression with functional enrichment scores

These approaches can help elucidate how UPP1-expressing cells shape the immunosuppressive TME and contribute to cancer progression and metastasis.

What methodologies are recommended for studying UPP1 in relation to cancer metastasis?

To investigate UPP1's role in cancer metastasis, researchers should consider these methodological approaches:

Animal Models:

• Use genetically engineered mouse models with UPP1 knockout or overexpression

• Analyze metastatic burden in lungs and other organs following primary tumor development

• Study the effect of UPP1 inhibition on metastatic colonization

Extracellular Matrix Analysis:

• Utilize UPP1 antibodies to correlate UPP1 expression with fibronectin deposition

• Perform immunohistochemistry on pre-metastatic niches

• Quantify ECM component changes (especially fibronectin) in response to UPP1 modulation

Immune Profiling:

• Analyze T-cell proliferation and function in relation to UPP1 expression

• Study neutrophil behavior and adhesion molecule expression

• Use cytometry by time-of-flight (CyTOF) analysis to comprehensively profile immune populations in UPP1high vs. UPP1low contexts

Patient-Derived Models:

• Establish patient-derived organoids (PDOs) from UPP1high and UPP1low tumors

• Test drug sensitivities (e.g., to kinase inhibitors like Bosutinib and Dasatinib)

• Correlate UPP1 expression with metastatic potential in PDO models

These approaches can provide mechanistic insights into how UPP1 contributes to metastatic progression and may reveal new therapeutic strategies.

How can researchers study the relationship between UPP1 and immune checkpoint regulation?

Recent findings indicate that UPP1 upregulation elevates PD-L1 expression through the PI3K/AKT/mTOR pathway, contributing to immunosuppression . To investigate this relationship, researchers should consider:

Signaling Pathway Analysis:

• Use UPP1 antibodies in combination with phospho-specific antibodies for PI3K/AKT/mTOR pathway components

• Perform Western blots or immunofluorescence to track signaling changes following UPP1 modulation

• Employ pathway inhibitors to determine causality in UPP1-mediated PD-L1 upregulation

Functional Immune Assays:

• Co-culture UPP1-manipulated tumor cells with T cells and measure:

  • T cell proliferation and activation markers

  • Cytokine production

  • Cytotoxic activity against tumor cells

• Compare results with and without PD-1/PD-L1 blocking antibodies

Translational Patient Sample Analysis:

• Perform multiplex immunohistochemistry on patient samples for:

  • UPP1 expression

  • PD-L1 levels

  • CD8+ T cell infiltration and activation state

• Correlate these parameters with clinical outcomes and response to immunotherapy

This integrated approach can help determine whether UPP1 inhibition could enhance immunotherapy efficacy by reducing PD-L1-mediated immunosuppression.

How should researchers address potential cross-reactivity issues with UPP1 antibodies?

Cross-reactivity can compromise experimental results. Researchers working with UPP1 antibodies should consider these approaches to address potential cross-reactivity:

Epitope Analysis:

• Review the immunogen sequence used to generate the antibody

• The sequence for many commercial UPP1 antibodies corresponds to amino acids 1-100 of human UPP1 (Q16831)

• Check this sequence against potential cross-reactive proteins using bioinformatics tools

Multi-antibody Validation:

• Use multiple antibodies targeting different UPP1 epitopes

• Compare staining/detection patterns across antibodies

• Consistent results across antibodies suggest specific detection

Species-Specific Considerations:

• Verify antibody reactivity for your species of interest (human, mouse, rat, etc.)

• When using antibodies across species, validate using appropriate positive and negative controls

• Consider species-specific sequence homology when interpreting results

Additional Controls:

• Include recombinant UPP1 protein as a positive control in Western blots

• Use competitive blocking with immunizing peptide

• Include tissues known to be negative for UPP1 expression as negative controls

When publishing results, clearly document the antibody used (including catalog number) and validation steps performed to allow proper interpretation and reproducibility.

What are the recommended approaches for quantifying UPP1 in research samples?

Accurate quantification of UPP1 is essential for comparative studies. Researchers should consider these methodological approaches:

Protein Quantification Methods:

• Western Blot: Use appropriate loading controls (β-actin, GAPDH)

  • Employ densitometry software for quantification

  • Consider using standard curves with recombinant UPP1

• ELISA: Provides more precise quantitative measurements

  • Particularly useful for measuring UPP1 in biological fluids or cell lysates

• Immunohistochemistry Quantification:

  • Use digital image analysis software

  • Consider H-score method (intensity × percentage of positive cells)

  • AI-based analysis platforms like Aipathwell have been used successfully

mRNA Quantification as Complementary Approach:

• qRT-PCR for UPP1 transcript levels

• RNA-seq data analysis

• Compare mRNA and protein levels to detect post-transcriptional regulation

Enzymatic Activity Assays:

• Measure UPP1 enzymatic activity using spectrophotometric assays

• Monitor conversion of uridine to uracil

• Correlate activity with protein levels determined by antibody-based methods

When reporting results, include detailed methodological information about quantification approaches, software used, and normalization methods to ensure reproducibility.

How can contradictory results with UPP1 antibodies be reconciled in research?

Researchers occasionally encounter contradictory results when using different UPP1 antibodies or across different experimental systems. To reconcile these discrepancies:

Antibody-Related Factors:

• Compare antibody characteristics:

  • Polyclonal vs. monoclonal (polyclonal may detect multiple epitopes/isoforms)

  • Host species and immunization protocol

  • Specific epitope recognized

• Consider that UPP1 has up to two reported isoforms , which may be differentially detected

Experimental Conditions:

• Examine differences in sample preparation:

  • Fixation methods and duration

  • Antigen retrieval protocols (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Blocking reagents and incubation conditions

• Compare protein extraction methods for Western blot

Biological Variables:

• UPP1 expression varies significantly across tissues (higher in small intestine, oral mucosa, esophagus)

• Expression may be altered in disease states (particularly cancer)

• Consider cellular heterogeneity within samples (single-cell analysis may reveal subpopulations)

Validation Approaches:

• Use genetic approaches (siRNA, CRISPR) to validate antibody specificity

• Employ alternative detection methods (mass spectrometry)

• Consider integrated approaches combining protein and transcript analysis

How can UPP1 antibodies be used to develop novel cancer prognostic tools?

Recent research has established that UPP1 expression correlates with poor prognosis in lung adenocarcinoma patients . Researchers interested in developing UPP1-based prognostic tools should consider:

Integrated Biomarker Approaches:

• Combine UPP1 with other prognostic markers

• Use multiplex immunohistochemistry to simultaneously detect UPP1 and immune cell markers

• Develop UPP1-related TME modules based on the marker genes of associated cell populations

AI-Enhanced Analysis:

• Implement AI-based software like Aipathwell for standardized quantification

• Develop algorithms that incorporate UPP1 expression with histological and clinical parameters

• Train models using retrospective cohorts and validate in prospective studies

These approaches could lead to the development of clinically useful prognostic tools based on UPP1 expression patterns in cancer.

What methodologies are recommended for exploring UPP1 as a therapeutic target?

For researchers investigating UPP1 as a potential therapeutic target, especially in cancer, these methodological approaches are recommended:

Pharmacological Inhibition Studies:

• Test established UPP1 inhibitors in preclinical models

• Measure effects on tumor growth, metastasis, and immune infiltration

• Evidence suggests that knockout or inhibition of UPP1 in mice with mammary tumors increases T-cell numbers, reduces fibronectin content in the lung, and decreases metastasis

Genetic Manipulation Approaches:

• Generate conditional UPP1 knockout models

• Use inducible systems to study temporal effects of UPP1 depletion

• Employ CRISPR-Cas9 to modify UPP1 in cancer cell lines and patient-derived models

Combination Therapy Assessment:

• Evaluate UPP1 inhibition combined with immunotherapy

• Test UPP1 inhibition with conventional chemotherapy

• Investigate UPP1 inhibition with targeted therapies (e.g., kinase inhibitors)

• Current research suggests UPP1high tumors exhibit relatively increased sensitivity to Bosutinib and Dasatinib

Translational Biomarker Development:

• Use UPP1 antibodies to identify patients likely to respond to UPP1-targeted therapies

• Develop companion diagnostic assays for future clinical trials

• Monitor changes in UPP1 expression during treatment as a response biomarker